May 07, 2026 | Angelini's $4.1B Catalyst Buyout; Atara Surges 40% on FDA Path Forward; Roche Acquires PathAI

Angelini Pharma pays $4.1B cash for Catalyst Pharmaceuticals — the fourth biotech buyout this month. Atara surges 40%+ on FDA path to resubmit tab-cel BLA. Roche acquires PathAI in $1B+ AI diagnostics deal. Duchenne takes two hits as Entrada data disappoint and Sarepta slides.Visit us at www. thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Angelini Pharma,Catalyst Pharmaceuticals, Firdapse, amifampridine, Lambert-Eaton myasthenicsyndrome, Atara Biotherapeutics, tabelecleucel, tab-cel, Pierre Fabre, Roche,PathAI, digital pathology, Entrada Therapeutics, ENTR-601-44, Duchenne musculardystrophy, Sarepta, Elevidys, EnGene, bladder cancer, Alnylam, Amvuttra,vutrisiran, Blackstone, Anagram Therapeutics, cystic fibrosis, Eli Lilly,manufacturing, Amazon, Ozempic, oral semaglutide, Novo Nordisk, MirumPharmaceuticals, volixibat, PSC, Argenx, Vyvgart, Leqembi, MannKind, Afrezza,M&A, rare disease, Lilly, Merck, AbbVie, Gilead, Bayer